News
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
— Key milestone for novel, resorbable breast / pectus reconstruction implants
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today reported encouraging one-year follow-up data of its breast and pectus excavatum scaffolds.
Both pectus and breast implants demonstrated a very good safety profile, were very well accepted by the surgeons and patients expressed high satisfaction and reported an improvement in quality of life. A significant improvement in pain scores was observed in breast reconstruction patients with prior silicone implants. All patients´ breasts maintained their shape and volume after surgery. Read more…
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
— Ongoing Phase IIb study expands to arm B
— 5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantation
— Second closing of Series A round
TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light by the Safety Board to initiate the B arm of the study. Read more…
BellaSeno Granted Market Access in Europe for Custom-Made Bone and Pectus Excavatum Scaffolds
— Market entry under new EU regulations for medical devices
— Spearheading the commercialization of 3D-printed regenerative medicine products
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that the Company has received authorization for its custom-made bone and pectus excavatum scaffolds in Europe under EU medical devices regulations
Cellbox Solutions GmbH Awarded €2.5 Million Grant Combined with an Equity Component of up to €10 Million Under the European Innovation Council´s Accelerator Program
– Cellbox Solutions selected by the EIC following the second 2023 EIC Accelerator cut-off
Cellbox Solutions GmbH, a leading provider of warm chain logistics solutions for the research, development and shipment of cell-based therapies and cellular diagnostics, today announced that the Company has been awarded an initial grant of €2.5 million combined with an additional equity funding of up to €10 million under the European Innovation Council (EIC) Accelerator program sponsored by the European Union.